Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Current RCC Treatment Limitations

January 29th 2021

Health care experts remark on current unmet needs associated with the use of novel therapies, such as immunotherapies, and targeted treatments for metastatic renal cell carcinoma and share advice on best practices when managing patients in the community.

Lenvatinib Combination Data in mRCC

January 29th 2021

Robert Alter, MD, highlights various trial data on the management of advanced renal cell carcinoma with the combination of lenvatinib and everolimus, also commenting on the potential outcomes associated with the use of lenvatinib with pembrolizumab.

Debate Ensues With Integrating Multimodal Approaches in RCC, Sequencing Agents in Bladder Cancer

January 27th 2021

During the question-and-answer portion of the virtual Institutional Perspectives in Cancer webinar, Earle Burgess, MD, and colleagues provide insight into how they are navigating the evolving treatment landscape of renal cell carcinoma and bladder cancer.

Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally

January 26th 2021

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

FDA Approval Insights: Nivolumab/Cabozantinib in Advanced RCC

January 25th 2021

In our exclusive interview, Toni K. Choueiri, MD, provides perspective on the FDA approval of nivolumab and cabozantinib in advanced renal cell carcinoma.

Avelumab Approved in Europe for Frontline Maintenance in Metastatic Urothelial Carcinoma

January 25th 2021

January 25, 2021 - The European Commission has approved avelumab for use as a frontline maintenance option in the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who did not progress after having received platinum-based chemotherapy.

Dr. Choueiri on the FDA Approval of Nivolumab/Cabozantinib in mRCC

January 22nd 2021

Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.

FDA Approves Nivolumab Plus Cabozantinib for Advanced RCC

January 22nd 2021

January 22, 2021 - The FDA has approved the combination of nivolumab plus cabozantinib for the frontline treatment of patients with advanced renal cell carcinoma.

Lenvatinib for mRCC

January 22nd 2021

Robert Motzer, MD, describes what lenvatinib is and explains the rationale for studying its use in combination with novel therapies such as everolimus as treatment for metastatic renal cell carcinoma.

Second-Line Treatment Approaches for mRCC

January 22nd 2021

Oncologists discuss their preferences in regard to second-line therapy for metastatic renal cell carcinoma, and optimal timing for changing regimens based on responses to treatment.

FDA Grants Priority Review to Retifanlimab for Squamous Cell Carcinoma of the Anal Canal

January 21st 2021

January 21, 2021 - The FDA has granted priority review to a biologics license application for retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who were intolerant of or who had progressed on platinum-based chemotherapy.

Forecasting Future Advances Across Oncology

January 21st 2021

Expert discuss their expectations for research and drug development in oncology in the new year.

The Role of Cytoreductive Nephrectomy Remains Uncertain in mRCC

January 21st 2021

Justin T. Matulay, MD, discusses whether there is a role for cytoreductive nephrectomy in metastatic renal cell carcinoma, as well as key data that have helped guide this paradigm.

FDA Grants Fast Track Status to Padeliporfin ImPACT for Upper-Tract Urothelial Cancer

January 18th 2021

January 18, 2021 — The FDA has granted a fast track designation to padeliporfin Immune Photo Activated Cancer Therapy for use in the treatment of patients with low-grade and unifocal upper-tract urothelial cancer.

More Than 2 Cycles of Cisplatin Significantly Reduces Risk of Second Testicular Cancer

January 15th 2021

January 15, 2021 - The risk of a second metachronous contralateral germ cell testicular cancer is found to be significantly reduced with each additional cycle of cisplatin-based chemotherapy in patients.

mRCC: Moving to Second-Line Therapy

January 15th 2021

Factors that prompt oncologists to move to second-line therapy to treat metastatic renal cell carcinoma.

Selecting Frontline Therapy for mRCC

January 15th 2021

Variables that influence an individualized first-line treatment approach for advanced renal cell carcinoma.

Making an Impact in the Fight Against GU Cancers as Scientist, Physician, and Teacher

January 12th 2021

Long before Dean F. Bajorin, MD, would travel the world as a renowned expert in genitourinary cancers—presenting at international conferences, working with major task forces, and changing the paradigms of care for patients in every corner of the globe—he began with a decidedly shorter journey: to college.

Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer

January 11th 2021

In our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.

Dr. Hutson on Challenges With Targeted Therapy in Non-Clear Cell RCC

January 8th 2021

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.